Library / Repair and recovery

Pentadeca arginate

Also known as PDA, BPC-157 arginate salt

Largely unstudied

Marketed as an arginate salt or variant of BPC-157. No peer reviewed studies of this specific form were found on PubMed.

Not an approved medicine. Pentadeca arginate is not an approved medicine for this use in Australia or the United States. This page summarises published research for information only. It is not a recommendation to use Pentadeca arginate, and VialOwl does not sell or supply it.

Background

Pentadeca arginate (PDA) is sold as a form of BPC-157, a 15 amino acid peptide originally described by a research group in Zagreb, Croatia, as a fragment of a protein in human gastric juice. PDA appears to be the same peptide sequence supplied as an arginine salt rather than the usual acetate salt, and it emerged through US compounding and wellness markets.

How it is thought to work

No studies of PDA itself exist, so any mechanism is borrowed from BPC-157 animal research, which proposes effects on blood vessel growth, nitric oxide signalling and tissue healing. A different salt form would not be expected to change how the peptide acts once dissolved.

What is claimed, and the evidence

Claim	Evidence	Notes
Tendon, ligament, muscle and gut healing	Animal studies only	Based on BPC-157 rodent studies; no published PDA studies.
More stable or better absorbed than BPC-157	No published evidence	Marketing claim from compounding sources; no peer reviewed data found.
Faster injury recovery, less pain and inflammation in people	No published evidence	User and clinic claims; no published human trials of PDA.

Side effects

Effect	How often	Notes
Any human side effects	Frequency unknown	No published human studies of PDA. For BPC-157, FDA identified no or only limited safety information.
Immune reactions to the product Serious	Frequency unknown	FDA flagged immunogenicity and impurity risks for compounded BPC-157.

Warnings

No peer reviewed study of pentadeca arginate was found; all claims rest on BPC-157 animal research.
BPC-157 itself is not approved anywhere, and FDA lacks enough information to know whether it causes harm in humans.
Unapproved products are not assessed by the TGA for quality, safety or efficacy and may be contaminated, non-sterile, underdosed, overdosed or contain a different substance altogether.

Regulatory status

Australia: Not included on the ARTG (unapproved). Not verified whether captured by the BPC-157 entry in the Poisons Standard.
United States: Not FDA approved. No FDA compounding category entry found.

Sources

Also in Repair and recovery

From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use Pentadeca arginate.